Volume : 11, Issue : 03, March – 2024
Title:
STRUCTURE ACTIVITY RELATIONSHIP (QSAR) IN THE CONTEXT OF NURAMINIDASE INHIBITORS
Authors :
C. Jhansi Rani
Abstract :
The H1N1 virus, known for its global impact on public health, continues to pose a significant threat, underscoring the need for effective antiviral strategies. Neuraminidase inhibitors have proven to be pivotal in mitigating the severity and spread of influenza viruses. In this study, we employ Quantitative Structure-Activity Relationship (QSAR) modeling to elucidate the molecular features influencing the inhibitory activity of compounds targeting the neuraminidase enzyme of the H1N1 virus.Molecular descriptors encompassing structural, physicochemical, and electronic properties are systematically selected to capture the essential features dictating the inhibitory potential of neuraminidase inhibitors.The mathematical models, whether linear or nonlinear, are developed through rigorous statistical analyses, emphasizing the interpretability of the relationships between molecular descriptors and biological activity. The acceptability domain is defined to ensure the reliability of predictions for structurally diverse compounds.The results showcase the robustness of the QSAR models in predicting the neuraminidase inhibitory activity of new compounds. Critical structural insights are uncovered, guiding the rational design of novel H1N1 virus neuraminidase inhibitors with enhanced efficacy and selectivity. The implications of these findings extend to the development of potential antiviral agents and contribute to the ongoing efforts to combat influenza outbreaks.Keywords: H1N1 virus, Neuraminidase inhibitors, Quantitative Structure-Activity Relationship (QSAR), Influenza, Antiviral drug design, Molecular descriptors, Biological activity.
Cite This Article:
Please cite this article in press C. Jhansi Rani., Structure Activity Relationship (QSAR) In The Context Of Nuraminidase Inhibitors., Indo Am. J. P. Sci, 2024; 11 (03).
Number of Downloads : 10
References:
1. Monto AS, Acuzio IA, LaMontague JR. Pandemic Influenza confornting reemergentthreat. Threat J.Infect. Dis. 1997;176:1–8.
2. Hayden FG, Belshe RB, Glover RD. Emergence and apparent transmission of rimantadine- resistant influenza A virus in families. N Engl. J. Med. . 1989;321:1696–1702.
3. Hay AJ, Wolstenholme AJ, Skehel JJ. The molecular basis of the specific anti-influenza action of amantidine. EMBOJ. 1985;4:3021–3024.
4. Hastings JC, Selnick HG, Wolanski BS, Tomassini ]JE. Anti-influenza virus activities of 4- substituted 2, 4-dioxobutanoic acid inhibitors. Antimicrob Agents Chemother. . 1996;40:1304– 1307.
5. Mammen M, Dahmann G, Whitesides GM. Effective inhibitors of hemagglutination by influenza virus synthesized from polymers having active ester groups. Insight into mechanism of inhibition. J. Med. Chem. . 1995;38:4179–4190.
6. Colman PM, Krug RM, editors. The Influenza Viruses: Influenza Virus Neuraminidase Enzyme and Antigenin the influenza viruses. New York: Plenum Press; 1989. pp. 175–218.
7. Erik De, Clercq J. Anti-viral drugs: current state of the art. Clin Virol. . 2001;22:73–89.
8. Gong J, Xu W, Zhang J. Structure and functions of influenza virus neuraminidase. Curr Med. Chem. 2007;14:113–122.
9. Varghese JN, Laver WG, Colman PM. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution. Nature. 1983;303:35–40.
10. Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2, 4-dideoxy-2,3-dehydro-N- acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets. Antimicrob Agents Chemother. 1995;39:2583–2584.
11. Verma RP, Hansch CA. QSAR study on influenza neuraminidase inhibitors. Bioorg Med. Chem. 2006;14:982–996.
12. Nair PC, Sobhia ME. Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors. Eur J. Med. Chem . 2008;43:293–299.
13. Golbraikh A, Tropsha A. Beware of q2. J Mol. Graph. Model . 2002;20:269–276.
14. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem. Inf. Comput. Sci. . 1994; 34:854–866.
15. Kubinyi H. Variable selection in QSAR studies. I. An evolutionary algorithm. Quant. Struct- Act. Relat. 1994;13:285–294.
16. SS, Karplus M. Evolutionary optimization in quantitative structure−activity relationship: an application of genetic neural networks. J Med. Chem. . 1996;39:1521–1530.
17. Kubinyi H, Hambrecht FA, Mietzner T. Three-dimensional quantitative similarity-activity relationships (3d qsar) from seal similarity matrices. J Med. Chem. . 1998;41:2553–2564.
18. Sun C, Zhang X, Huanga H, Zhou P. Synthesis and evaluation of a new series of substituted acyl(thio)urea and thiadiazolo [2,3-a] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase Bioorg. Med Chem. . 2006;14:8574–8581.
19. Ajmani S, Jadhav K, Kulkarni SA. Three-dimensional QSAR using the k-nearest neighbor method and its interpretation. J Chem. Inf. Model. . 2006; 46:24–31.
20. VLifeMDS. India: V-life Sciences Technologies Pvt Ltd; 2004. Molecular Design Suite version 3.5.
21. Zheng W, Tropsha A. Novel variable selection quantitative structure-property relationship approach based on the k-nearest-neighbor principle. Chem Inf. Comput. Sci. 2000;40:185– 194.
22. Ajmani S, Jadhav K, Kulkarni SJ. Three-dimensional QSAR using the k-nearest neighbor method and its interpretation. Chem Inf. Comput. Sci. 2006; 40:24–31.
23. Wang T, Wade RC. Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes. J Med. Chem. 2001;44:961–971.
24. Wang GT, Chen Y, Wang S, Gentles R, Sowin T, Muchmore W, Kati S, Giranda V, Stewart K, Sham HL, Kempf D, Laver WG. Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J Med. Chem. . 2001;44:1192–1201.
25. Taylor NR, Von Itzstein M. Molecular modelling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Comput. Aided Mol. Des. . 1996;10:233– 246.
26. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med. Chem. . 2006;49:6177–6196.
27. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol. . 2008;82:10493–10501.
28. Pozzan A. Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. Curr Pharm. Des. . 2006;12:2099–2110.
29. Hawkins PC, Skillman AG, Nicholls A. Comparison of shape-matching and docking as virtual screening tools. J Med. Chem. . 2007; 50:74–82.
30. Meclellan LM, Sokol LM, Kontoyiamn M. Evaluation of docking performance: comparative data on docking algorithms. J Med. Chem. 2004;47:558–565.